Department of Obstetrics and Gynecology, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany.
Am J Perinatol. 2024 Jun;41(8):1027-1032. doi: 10.1055/a-1787-3838. Epub 2022 Mar 3.
Cord gas values and Apgar scores, currently used as markers for newborn wellbeing and postpartum complications, provide rough estimates, and their use remains elusive. Circulating cell-free DNA (cfDNA) may better represent newborn status at birth and the effect of parturition on the fetus. This pilot study investigates the association between cord blood (CB) cfDNA and neonatal outcomes.
In a prospective cohort study, cfDNA concentration was measured in immediately following delivery collected CB sera of newborns using our rapid fluorescent assay.
During the study period, blood samples from umbilical cords of 100 newborns were collected. Vaginal delivery was associated with a higher median CB cfDNA than cesarean delivery (277 [95% confidence interval [CI] 199-377] vs. 100 [95% CI 43-265] ng/mL, < 0.01). cfDNA levels were significantly associated with gestational age at delivery (rho = 0.308, = 0.002) and CB base deficit (BD, = 0.252, = 0.017). According to maternal and fetal complications, CB cfDNA was elevated in fetuses with category II of heart rate tracing ( < 0.05), with maternal positive vaginal culture ( < 0.01), and with premature rupture of membranes (PROM, < 0.001). Logistic regression models of CB cfDNA fourth quartiles demostrate a double odds ratio for elevated BD (>3mmol/L) and for worse heart rate tracing category.
Serum CB cfDNA concentration reflects the newborn's status and hazards with an excellent association with CB BD, fetal heart rate category, and maternal risk factors for infection (positive vaginal culture and PROM). This preliminary observation suggests that cfDNA can serve as a point of care biomarker for newborn status at the time of delivery.
· CB cfDNA levels correlated with newborn's BD.. · CB cfDNA levels reflect parturition stress and inflammation.. · cfDNA serve as a diagnostic and prediction tool for the identification of newborns at risk for morbidity..
目前,脐带血值和阿普加评分被用作衡量新生儿健康状况和产后并发症的标志物,但这些标志物只能提供大致的估计,其实际应用效果仍不明确。循环无细胞 DNA(cfDNA)可能更能反映新生儿出生时的状态以及分娩对胎儿的影响。本研究旨在探讨脐带血(CB)cfDNA 与新生儿结局之间的关系。
在一项前瞻性队列研究中,我们使用快速荧光测定法检测了新生儿娩出后立即采集的 CB 血清中的 cfDNA 浓度。
在研究期间,共采集了 100 例新生儿脐带血样本。与剖宫产相比,阴道分娩的 CB cfDNA 中位数更高(277 [95%置信区间 [CI] 199-377] 与 100 [95% CI 43-265]ng/ml, < 0.01)。cfDNA 水平与分娩时的胎龄(rho = 0.308, = 0.002)和 CB 碱剩余(BD)显著相关(rho = 0.252, = 0.017)。根据母婴并发症,cfDNA 在胎心率图 II 类( < 0.05)、母亲阴道培养阳性( < 0.01)和胎膜早破(PROM, < 0.001)的胎儿中升高。CB cfDNA 第四四分位数的逻辑回归模型显示,BD(>3mmol/L)升高和胎心率图类别较差的双重优势比。
血清 CB cfDNA 浓度反映了新生儿的状况和危险,与 CB BD、胎儿心率类别以及感染的母体危险因素(阴道培养阳性和 PROM)具有极好的相关性。这一初步观察表明,cfDNA 可以作为分娩时新生儿状态的即时护理生物标志物。
·CB cfDNA 水平与新生儿 BD 相关。·CB cfDNA 水平反映分娩应激和炎症。·cfDNA 可作为一种诊断和预测工具,用于识别有发病风险的新生儿。